Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
40 hedge funds and large institutions have $6.87M invested in Unity Biotechnology in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 11 closing their positions.
5,727% more call options, than puts
Call options by funds: $4.08M | Put options by funds: $70K
31% more capital invested
Capital invested by funds: $5.24M → $6.87M (+$1.63M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.3% less ownership
Funds ownership: 22.05% → 18.75% (-3.3%)
13% less funds holding
Funds holding: 46 → 40 (-6)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$114K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 3 |
VF
Virtu Financial
New York
|
+$47.4K |
| 4 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
+$30.2K |
| 5 |
BlackRock
New York
|
+$19.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$761K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$153K |
| 3 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$142K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$102K |
| 5 |
Renaissance Technologies
New York
|
-$92.4K |
UBX Hedge Fund Activity: Q2 2023 in Review
40 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2023, worth a combined $6.87M — up 31% from $5.24M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of UBX and 5 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Wells Fargo, adding an estimated $114K. The largest seller was Fidelity Investments, cutting an estimated $761K.
- 40 institutional investors held Unity Biotechnology (UBX) as of Q2 2023, down from 46 in Q1 2023.
- Funds reported $6.87M of Unity Biotechnology stock for Q2 2023, up 31% quarter-over-quarter.
- 5 funds opened new Unity Biotechnology positions in Q2 2023 and 11 closed out, a net change of -6 holders.
- The largest Unity Biotechnology buyer in Q2 2023 was Wells Fargo, an estimated $114K added.
- The largest Unity Biotechnology seller in Q2 2023 was Fidelity Investments, an estimated $761K sold.
Based on aggregated 13F filings for Q2 2023.